I think they are contrasting . I beleivr MRTX has more potential utilizjng assay screening in early stage trials. I wish cldx would have done better job on validating more precise gentic populations for trials. I think theh optrd for throw all the darts and hop one sticks
excactly hence why institutional % is so low and the ones who are involved are short sellers. Well put
this was failed out of the gate. any form for doxorubicin has failed . More chemo equals more withrdrawals. and aldo was at 350 to 250 dose equiv of dox. If the drug had any chance it was at the same or lower dosage than 250. if you could achieve the same outcome with less side effects you have an apporoval . So prelim data showed cherry picked cases. Look they had clinical holds on the trial what did you expect. It was a p & D . anyone with half a brain would realize that this is not where cancer treatment is going . CAR T , ASSAY screening , ADC, Immune therapies and low dose short interval chemo is far better than aldo. People who have cancer sometimes grasp at the wrong straws . I feel sorry for people who were treated and died or suffered on CYTR's aldo trial . CEO should be ashamed dispicable fraud out for himself . I never owned this garbage. Sorry to be harsh but companies like this are #$%$. POINT PERIOD END OF STORY
If the science has a high level of efficacy a wise investor would spread to other car t companies. I like Blcm and intrexon as alternates. I am not selling this low nor am I a adding
Biomarin outsourced firdapse in us to cprx. BMRN gained approval in EU. Cprx cretes earnings for bmrn in us once cprx gains approval. Cprx then has cash to fund operations. You may see news of one of theor phase 2 drugs being partnered by another pharma. It is a recipe for big returns . you shouldnr have played cprx into fda review you play in after the fda agrees to secondary small p3 trial . we know 90%of eu approved drugs get fda nod.
Your naive. They are fighting a baseless faction of anti gmo lobbyists and poloticians. They scream global warmkng and save the whales but they are fine importing salmon from china rather than allow a us company to finally compete with china on cost to produce farmed salmon. Evwntually level heads prevail. Monsanto will buy th food divisionnin 3 years. Bio will be worth 40 in 5.
Idra is like xoma in more ways than one. What did bakers learn from xoma ? Get in low , get on board, get offerings on the way up. End up with options to protect your investment in the event of complete failure on closest clinical trial. I think if you buy here you are going to make some coin for sure
This smells like xoma in 2012 . Baker man baker bake me a cake . Add yeast to 1 cup of flour and make it to a to a 6 cup cake
IMO8400 ultra ultra orphan less than 900 cases in US . Here is the good thing this company could charge a huge tag if it makes it to market. Here is the tough side FDA has treated small trials with shear intollerance for anything but a jesus like cure to 100% of teh patients. Its early but if the science holds weight and the no one is in the market nor will anyone be entering anytime soon. So if they watch their dollars and design the trial to hit the marks FDA wants I would say we have a 55/45 shot at 8400 seeing market
I pittyafool who doeant buy mr tony ts double double stock pick of second half of 2016 . Target 6.50
The key is sgyp has no partner and has negative equity. They are riskier due to their insolvency. Cfo left his prior company then went bankrupt a few years latr. Sgyp They cannot scale a sales force and manufacture drug eith their balance sheet. They becomw like mankind if no partner or acquisition occurs. Long way to january. That being said it gets approved . yet approval and roi for investors are two entirelg different things